Bachem Holding AG (BANB.SW)
Bachem Holding AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Bubendorf, BL, CH. The stock last traded at $73.75, down 1.14% on the session, giving a market capitalisation of $5.53B. Its beta of 0.80 implies it has historically moved less than the broad market.
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Bachem Holding AG is most often compared with the following Healthcare names: